30 Participants Needed

SBRT for Kidney Cancer

(AQuOS-RCC Trial)

Recruiting at 1 trial location
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Sunnybrook Health Sciences Centre
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 4 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

Stereotactic body radiotherapy (SBRT) is an emerging radiotherapy technique that precisely delivers high doses of radiation to tumours. It has been investigated as definitive treatment for an increasing variety of primary tumours including lung, liver, prostate, and now renal cell carcinoma (RCC). The principal aims of this study are to prospectively assess quality of life (QoL) and oncologic outcomes in non-surgical patients who receive SBRT for the treatment of RCC.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is SBRT/SABR safe for treating kidney cancer?

Research shows that SBRT/SABR is generally safe for treating kidney cancer, with studies reporting favorable safety profiles and manageable side effects. It is a non-invasive treatment option that has been used successfully in patients who cannot undergo surgery.12345

How is the treatment SBRT different from other treatments for kidney cancer?

SBRT (Stereotactic Body Radiation Therapy) is unique because it is a non-invasive treatment that precisely targets kidney tumors, minimizing damage to surrounding healthy tissue. It is particularly beneficial for patients who cannot undergo surgery, offering a viable alternative with promising long-term safety and efficacy.35678

What data supports the effectiveness of the treatment SBRT for kidney cancer?

Research shows that stereotactic ablative radiotherapy (SABR), which is similar to SBRT, is a promising treatment for kidney cancer, with studies indicating it is safe and effective for treating primary renal cell carcinoma. It has been shown to manage kidney cancer while preserving kidney function by reducing radiation exposure to healthy kidney tissue.357910

Are You a Good Fit for This Trial?

This trial is for adults who can't have surgery or choose not to, with kidney tumors larger than 2.5cm or recurring after treatment. They should be diagnosed with renal cell carcinoma (RCC) if possible, or show tumor growth on scans.

Inclusion Criteria

My kidney cancer diagnosis was confirmed by a biopsy or by growth seen on scans.
My cancer lesion is larger than 2.5cm or has come back after treatment.
I cannot undergo surgery for medical reasons or I choose not to have surgery.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Radiation

Participants receive stereotactic body radiation therapy (SBRT) for the treatment of renal cell carcinoma

1-2 weeks
5 visits (in-person)

Follow-up

Participants are monitored for quality of life, oncologic outcomes, and treatment-related toxicity

Up to 5 years

What Are the Treatments Tested in This Trial?

Interventions

  • SBRT
Trial Overview The study tests Stereotactic body radiotherapy (SBRT), a high-precision radiation therapy aimed at treating non-surgical patients with RCC to see how it affects their quality of life and cancer control.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: SBRTExperimental Treatment1 Intervention
RCC patients

SBRT is already approved in United States, European Union, Canada, Japan for the following indications:

🇺🇸
Approved in United States as SBRT for:
  • Prostate cancer
  • Lung cancer
  • Liver cancer
  • Pancreatic cancer
  • Spinal tumors
🇪🇺
Approved in European Union as SBRT for:
  • Prostate cancer
  • Lung cancer
  • Liver cancer
  • Pancreatic cancer
  • Spinal tumors
  • Bone metastases
🇨🇦
Approved in Canada as SBRT for:
  • Prostate cancer
  • Lung cancer
  • Liver cancer
  • Pancreatic cancer
  • Spinal tumors
🇯🇵
Approved in Japan as SBRT for:
  • Prostate cancer
  • Lung cancer
  • Liver cancer
  • Pancreatic cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Sunnybrook Health Sciences Centre

Lead Sponsor

Trials
693
Recruited
1,569,000+

Juravinski Cancer Center

Collaborator

Trials
14
Recruited
2,300+

Published Research Related to This Trial

In a study of 62 kidney cancer patients treated with stereotactic ablative body radiotherapy (SABR), eliminating respiratory motion significantly reduced the dose received by the healthy kidney, with a reduction of 12 cc of kidney volume receiving 50% of the prescription dose for each centimeter of tumor motion amplitude.
The study also found that removing respiratory motion improved estimated renal function, with a gain of 4.4% in glomerular filtration rate (GFR) for each centimeter of motion eliminated, indicating a potential benefit for kidney health during SABR treatment.
Reducing the impact on renal function of kidney SABR through management of respiratory motion.Gaudreault, M., Siva, S., Kron, T., et al.[2021]
Stereotactic ablative radiotherapy (SABR) is a well-tolerated and effective treatment for primary renal cell carcinoma, showing high rates of local control (97.8%) and cancer-specific survival (95.7%) at 2 years among 223 patients studied across multiple institutions.
Patients receiving single-fraction SABR had better progression-free survival and cancer-specific survival compared to those receiving multifraction SABR, suggesting that single-fraction treatment may be more beneficial for certain patients.
Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).Siva, S., Louie, AV., Warner, A., et al.[2022]
In a study of 74 patients with localized renal cell carcinoma treated with stereotactic body radiotherapy (SBRT), the oncological outcomes were promising, with low rates of local failure (7.77% at 4 years) and distant metastasis (4.24% at 2 years).
However, there was a notable decline in renal function over time, with a median decrease in estimated glomerular filtration rate (eGFR) of -11.5 ml/min at 2 years, particularly in the treated kidney, while the contralateral kidney showed compensatory improvement.
Stereotactic Body Radiotherapy for Renal Cell Carcinoma: Oncological and Renal Function Outcomes.Glicksman, RM., Cheung, P., Korol, R., et al.[2023]

Citations

Reducing the impact on renal function of kidney SABR through management of respiratory motion. [2021]
Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). [2022]
Stereotactic Body Radiotherapy for Renal Cell Carcinoma: Oncological and Renal Function Outcomes. [2023]
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). [2023]
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial. [2022]
Stereotactic ablative radiotherapy for primary renal cell carcinoma. [2023]
Nephron-Sparing Robotic Radiosurgical Therapy for Primary Renal Cell Carcinoma: Single-Institution Experience and Review of the Literature. [2022]
Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. [2022]
Stereotactic Body Radiotherapy for Localized Kidney Cancer. [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
Radiation therapy options in kidney cancer. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security